|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
2/15/2013 9:33:37 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that new preclinical data demonstrating the differentiated potent and selective CYP17 lyase inhibition mechanism of action of its lead candidate, galeterone (TOK-001), will be presented today in a poster presentation titled, “Galeterone, Abiraterone, Orteronel and Ketoconazole Exhibit Differential Inhibitory Effects on CYP17 and Steroidogenesis,” abstract number 184, at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in Orlando, Fla.
|
|
|
|
|
|
|
|
|
|
|